第十一批国家集采纳入55种药品

Core Insights - The eleventh batch of national organized drug procurement has produced selection results, including 55 types of commonly used drugs across various fields such as anti-infection, anti-allergy, anti-tumor, blood sugar reduction, blood pressure reduction, blood lipid reduction, and anti-inflammatory pain relief [1] - The procurement aims to achieve goals of stabilizing clinical use, ensuring quality, preventing excessive competition, and avoiding collusion [1] - The selection process has become more competitive compared to previous batches, but measures such as excluding products with a scale below 100 million, setting "anchor prices" to prevent extreme low-price impacts, and introducing a revival mechanism have maintained a relatively high selection rate [1] Summary by Categories Procurement Details - A total of 55 drugs were included in this procurement round, covering essential therapeutic areas [1] - The average price difference of selected products has significantly narrowed compared to previous batches, indicating effective measures against excessive competition [1] Quality Assurance - Bidding companies are required to have experience in producing similar types of drugs, and production lines must not have violated quality management regulations in the past two years [1] - The drug regulatory authority will conduct comprehensive supervision and inspection of selected products post-procurement [1] Future Implications - The results of this procurement round will be officially announced, with expectations that patients nationwide will have access to high-quality and affordable selected drugs by February 2026 [1]